Page 68 - Read Online

Tang et al. Neuroimmunol Neuroinflammation 2021;8:64-9 Neuroimmunology
DOI: 10.20517/2347-8659.2020.28 and Neuroinflammation

Technical Note Open Access

Resection of orthotopic murine brain glioma

Bingtao Tang , Kari Foss , Terence Lichtor , Heidi Phillips , Edward Roy 1
2
3
1
2
1 Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
2 Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61802, USA.
3 Carle Illinois College of Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Correspondence to: Dr. Edward Roy, Department of Molecular and Integrative Physiology, University of Illinois at Urbana-
Champaign, 524 Burrill Hall, 407 S. Goodwin Ave, Urbana, IL 61801, USA. E-mail: eroy@illinois.edu

How to cite this article: Tang B, Foss K, Lichtor T, Phillips H, Roy E. Resection of orthotopic murine brain glioma. Neuroimmunol
Neuroinflammation 2021;8:64-9. http://dx.doi.org/10.20517/2347-8659.2020.28

Received: 6 Apr 2020 First Decision: 6 Jun 2020 Revised: 22 Jun 2020
Accepted: 1 Jul 2020 Fisrt online: 1 Sep 2020 Published: 21 Mar 2021

Academic Editor: Terry Lichtor, Dale Ding Copy Editor: Cai-Hong Wang Production Editor: Jing Yu

Abstract
Glioma is a malignant brain tumor with a poor prognosis. Surgical resection is usually the first line of treatment.
However, animal models of glioma do not include surgical resection and tumors are typically treated before they
become advanced. This report demonstrates the feasibility of surgical resection of advanced gliomas in mice. The
described technique establishes a murine model which could be used for the development of immunotherapy for
advanced glioma after surgical resection. Use of surgical resection in murine models could increase the probability
that therapies developed in mice will translate to human patients.

Keywords: Glioma, surgical resection, immunotherapy, overcoming immunosuppression, surgical stress, prolonged
survival

INTRODUCTION
Glioma is a type of brain or spinal cord tumor that originates from glial cells; 80% of all malignant brain
[1]
tumors are gliomas . These tumors are typically asymptomatic in people until they reach an advanced
stage. The standard of care for glioma includes surgery, radiotherapy and chemotherapy. Combining
radiotherapy with the chemotherapy agent temozolomide may prolong survival and delay tumor
[2]
progression modestly . Despite the current standard of care, prognosis for glioma patients remains poor:
the median survival for high-grade glioma, glioblastoma, is about 12-15 months with only 5% patients

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.nnjournal.net